Abstract
Previously, we have reported that tumor necrosis factor receptor super-family member 6b (TNFRSF6B) is overexpressed in glioma tissues, as well as in the supernatant of cultured glioma cells. However, the function of TNFRSF6B in glioma remains unclarified. The aim of the study was to investigate the effect of anti-TNFRSF6B neutralization monoclonal antibody on the malignant phenotype of glioma cells in vitro. Three glioma cell lines U251MG, LN-308 and U87MG were treated with anti-TNFRSF6B antibody. Cell growth, cell cycle, apoptosis and relevant downstream signaling were detected further. We found that anti-TNFRSF6B antibody inhibited cell growth and induced apoptosis in time and dose-dependent manners in the glioma cells tested. Cell cycle was also arrested in G1/S-phase. Furthermore, anti-TNFRSF6B antibody downregulated the level of MMP-2, phospho-ERK1/2 and phospho-AKT. In conclusion, anti-TNFRSF6B treatment might be acritical targeted therapy strategy for gliomas due to its contribution to suppress cell growth and induce apoptosis.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
